Literature DB >> 28848851

The Natural History of Lung Function in Severe Deficiency of Alpha-1 Antitrypsin Following Orthotopic Liver Transplantation: A Case Report.

Vickram Tejwani1, Xiao-Feng Wang2, James K Stoller3.   

Abstract

PI*ZZ alpha-1 antitrypsin (AAT) deficiency poses risk for lung disease through 2 different mechanisms: a toxic loss of function in which deficient AAT levels cause a depleted proteolytic screen and, separately, a proinflammatory effect of Z polymers produced both by alveolar macrophages and by the liver. Ample data support the first mechanism, while the possible contribution of the second 2 proinflammatory mechanisms is currently unknown. Experience with a 74 year-old PI*ZZ female who underwent single lung transplantation and subsequent orthotopic liver transplantation (OLT) may shed light on the relative contributions of each of the potential mechanisms. Availability of multiple pulmonary function tests (PFT) measurements uniquely permitted calculation of rates of lung function change before and after OLT. The rate of forced expiratory volume in 1 second (FEV1) decline normalized post-OLT (from -60 to -21 ml/yr). Her course suggests that restoring the normal serum AAT levels or, alternately, eliminating liver-derived polymers, exerted a greater effect on preventing emphysema progression than local Z polymer production contributed to furthering emphysema.

Entities:  

Keywords:  alpha-1 antitrypsin deficiency; emphysema; transplant

Year:  2015        PMID: 28848851      PMCID: PMC5556825          DOI: 10.15326/jcopdf.2.4.2015.0141

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  15 in total

1.  A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy.

Authors:  A Dirksen; J H Dijkman; F Madsen; B Stoel; D C Hutchison; C S Ulrik; L T Skovgaard; A Kok-Jensen; A Rudolphus; N Seersholm; H A Vrooman; J H Reiber; N C Hansen; T Heckscher; K Viskum; J Stolk
Journal:  Am J Respir Crit Care Med       Date:  1999-11       Impact factor: 21.405

2.  American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2003-10-01       Impact factor: 21.405

3.  Acquired PiZZ alpha-1 antitrypsin deficiency in a liver transplant recipient.

Authors:  Francisco M Arnal; Maria J Lorenzo; Francisco Suárez; Alejandra Otero; Clara Alonso; Purificación Filgueira; Manuel Gómez
Journal:  Transplantation       Date:  2004-06-27       Impact factor: 4.939

4.  Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency.

Authors:  D G Parr; B C Stoel; J Stolk; R A Stockley
Journal:  Thorax       Date:  2006-03-14       Impact factor: 9.139

5.  Outcomes for recipients of liver transplantation for alpha-1-antitrypsin deficiency–related cirrhosis.

Authors:  Elizabeth J Carey; Vivek N Iyer; Darlene R Nelson; Justin H Nguyen; Michael J Krowka
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

6.  Effect of liver transplant on pulmonary functions in adult patients with alpha 1 antitrypsin deficiency: 7 cases.

Authors:  Ashokkumar B Jain; Vrishali Patil; Baber Sheikh; Michael Apostolakos; Charlotte Ryan; Randeep Kashyap; Mark Orloff
Journal:  Exp Clin Transplant       Date:  2010-03       Impact factor: 0.945

7.  The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort.

Authors:  Robab Kohansal; Pablo Martinez-Camblor; Alvar Agustí; A Sonia Buist; David M Mannino; Joan B Soriano
Journal:  Am J Respir Crit Care Med       Date:  2009-04-02       Impact factor: 21.405

8.  Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.

Authors:  P A Dawkins; C L Dawkins; A M Wood; P G Nightingale; J A Stockley; R A Stockley
Journal:  Eur Respir J       Date:  2009-01-22       Impact factor: 16.671

9.  Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.

Authors:  A Dirksen; E Piitulainen; D G Parr; C Deng; M Wencker; S B Shaker; R A Stockley
Journal:  Eur Respir J       Date:  2009-02-05       Impact factor: 16.671

10.  Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase.

Authors:  Danny Jonigk; Mariam Al-Omari; Lavinia Maegel; Meike Müller; Nicole Izykowski; Jaewoo Hong; Kwangwon Hong; Soo-Hyun Kim; Martina Dorsch; Ravi Mahadeva; Florian Laenger; Hans Kreipe; Armin Braun; Galit Shahaf; Eli C Lewis; Tobias Welte; Charles A Dinarello; Sabina Janciauskiene
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.